113 related articles for article (PubMed ID: 29807777)
1. The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis.
Li X; Pu J; Liu J; Chen Y; Li Y; Hou P; Shi B; Yang Q
Pathol Res Pract; 2018 Jul; 214(7):940-948. PubMed ID: 29807777
[TBL] [Abstract][Full Text] [Related]
2. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of Death-Associated Protein Kinase (DAPK1) and its association with oral carcinogenesis - An experimental and meta-analysis study.
Jayaprakash C; Varghese VK; Bellampalli R; Radhakrishnan R; Ray S; Kabekkodu SP; Satyamoorthy K
Arch Oral Biol; 2017 Aug; 80():117-129. PubMed ID: 28412611
[TBL] [Abstract][Full Text] [Related]
4. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
5. Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer.
Wang N; Sui F; Ma J; Su X; Liu J; Yao D; Shi B; Hou P; Yang Q
Arch Med Res; 2016 May; 47(4):285-92. PubMed ID: 27664488
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Zhang L; Wang M; Wang W; Mo J
J Neurooncol; 2014 Jan; 116(2):349-56. PubMed ID: 24197988
[TBL] [Abstract][Full Text] [Related]
7. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
8. Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker.
Giachelia M; Bozzoli V; D'Alò F; Tisi MC; Massini G; Maiolo E; Guidi F; Cupelli E; Martini M; Larocca LM; Voso MT; Leone G; Hohaus S
J Mol Diagn; 2014 Jul; 16(4):467-76. PubMed ID: 24814955
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation and expression of DAPk1 in human hypopharyngeal squamous cell carcinoma.
Wei DM; Liu DY; Lei DP; Jin T; Wang J; Pan XL
Acta Otolaryngol; 2015 Jan; 135(1):70-8. PubMed ID: 25496179
[TBL] [Abstract][Full Text] [Related]
10. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
11. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas.
Zhang Z; Li D; Wu M; Xiang B; Wang L; Zhou M; Chen P; Li X; Shen S; Li G
BMC Mol Biol; 2008 Nov; 9():99. PubMed ID: 18976507
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes.
Wu X; Liu W; Tian Y; Xiao M; Wu Y; Li C
Acta Haematol; 2011; 125(4):179-85. PubMed ID: 21212658
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
17. Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation.
Candiloro IL; Mikeska T; Dobrovic A
Epigenetics; 2011 Apr; 6(4):500-7. PubMed ID: 21364322
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma.
Al-Moundhri MS; Al-Nabhani M; Tarantini L; Baccarelli A; Rusiecki JA
PLoS One; 2010 Dec; 5(12):e15585. PubMed ID: 21203466
[TBL] [Abstract][Full Text] [Related]
19. Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas.
Kilinc D; Ozdemir O; Ozdemir S; Korgali E; Koksal B; Uslu A; Gultekin YE
DNA Cell Biol; 2012 May; 31(5):826-32. PubMed ID: 22136354
[TBL] [Abstract][Full Text] [Related]
20. Association of aberrant DNA methylation with clinicopathological features in breast cancer.
Tserga A; Michalopoulos NV; Levidou G; Korkolopoulou P; Zografos G; Patsouris E; Saetta AA
Oncol Rep; 2012 May; 27(5):1630-8. PubMed ID: 22159596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
